Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

Objective: To determine the recurrence rate and survival among early-stage epithelial ovarian cancer cases considering homologous recombination deficiency (HRD) status. Methods: Single institution retrospective study of stage I/II EOC patients from 2017 to 2020. HRD was defined as evidence of germli...

Full description

Bibliographic Details
Main Authors: Monica D. Levine, David M. O'Malley, Paulina J. Haight, Leigha Senter, Vincent Wagner, Kristin L. Bixel, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Eric M. McLaughlin, Floor J. Backes
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578923000425

Internet

http://www.sciencedirect.com/science/article/pii/S2352578923000425

Similar Items